UNSPSC 51322204: Acifran

This classification denotes an anti-lipidemic agent with the molecular formula C12H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B1X701S0MV, chemically known as 4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furancarboxylic acid but generally known as acifran, which bears US NIH Compound Identifier 51576. European Medicines Agency schedules Acifran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05236MIG. The term ACIFRAN is an International Non-Proprietary Name.

UNSPSC 51322204 Acifran, a Commodity code, encompasses emergency and critical-care medications that state and local governments—primarily emergency medical services agencies and public health systems—procure for field administration and institutional use. Recent solicitations show active purchasing of specific injectable formulations including epinephrine, labetalol, adenosine, and diltiazem for advanced life support protocols, as well as broader generic pharmaceutical and OTC product sourcing through cooperative purchasing vehicles. The code captures both direct-buy emergency medication contracts with firm pricing and expiration-date guarantees, and multi-year framework agreements leveraging state and local cooperative purchasing alliances to supply networked wholesalers and participating government facilities across multiple jurisdictions.

Issuing bodies under this code span city fire and rescue departments, state health agencies, and multi-state cooperative purchasing organizations. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (Bid 26P00188) as an IFB due April 8, 2026, with estimated contract value of $40,000 for Tampa Fire Rescue's operational supply, including a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP for Generic Multi Source Pharmaceuticals and OTC Products due March 26, 2026, establishing multi-award contracts effective July 1, 2026 for distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson across participating state and local facilities in Minnesota and Oregon. Recent activity concentrates in Florida, Texas, and the Upper Midwest, with geographic spread reflecting both individual city and regional cooperative purchasing networks.